Shabnam Baig

Summary

Affiliation: University of Bristol
Country: UK

Publications

  1. doi Clusterin mRNA and protein in Alzheimer's disease
    Shabnam Baig
    Dementia Research Group, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK
    J Alzheimers Dis 28:337-44. 2012
  2. ncbi Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease
    Shabnam Baig
    Department of Clinical Science at North Bristol, Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol, UK
    Acta Neuropathol 110:393-401. 2005
  3. doi Tau hyperphosphorylation affects Smad 2/3 translocation
    S Baig
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol BS16 1LE, UK
    Neuroscience 163:561-70. 2009
  4. pmc Distribution and expression of picalm in Alzheimer disease
    Shabnam Baig
    Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, United Kingdom
    J Neuropathol Exp Neurol 69:1071-7. 2010
  5. pmc Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta
    Jennifer C Palmer
    Dementia Research Group, Frenchay Hospital, Bristol, United Kingdom
    Am J Pathol 175:262-70. 2009
  6. doi Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity
    James Scott Miners
    Dementia Research Group, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom
    J Neuropathol Exp Neurol 68:902-14. 2009
  7. doi Abeta-degrading enzymes in Alzheimer's disease
    James Scott Miners
    Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK
    Brain Pathol 18:240-52. 2008

Detail Information

Publications7

  1. doi Clusterin mRNA and protein in Alzheimer's disease
    Shabnam Baig
    Dementia Research Group, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK
    J Alzheimers Dis 28:337-44. 2012
    ..The increase in clusterin noted in peripheral blood in AD may reflect increased passage of this chaperone protein across the blood-brain barrier but further work is needed to determine how CLU variants influence the development of AD...
  2. ncbi Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease
    Shabnam Baig
    Department of Clinical Science at North Bristol, Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol, UK
    Acta Neuropathol 110:393-401. 2005
    ..This could in turn lead to increased activity of the glutamatergic and other neurons onto which they synapse...
  3. doi Tau hyperphosphorylation affects Smad 2/3 translocation
    S Baig
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol BS16 1LE, UK
    Neuroscience 163:561-70. 2009
    ..This may compromise neuroprotective actions of TGFbeta and contribute to neurodegeneration in AD...
  4. pmc Distribution and expression of picalm in Alzheimer disease
    Shabnam Baig
    Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, United Kingdom
    J Neuropathol Exp Neurol 69:1071-7. 2010
    ..Further research is needed to determine whether PICALM expression is influenced by Aβ levels and whether it affects Aβ uptake and transport by endothelial cells...
  5. pmc Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta
    Jennifer C Palmer
    Dementia Research Group, Frenchay Hospital, Bristol, United Kingdom
    Am J Pathol 175:262-70. 2009
    ..Our findings suggest that endothelin-1 receptor antagonists, already licensed for treating other diseases, could be of benefit in AD therapies...
  6. doi Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity
    James Scott Miners
    Dementia Research Group, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom
    J Neuropathol Exp Neurol 68:902-14. 2009
    ..Our findings suggest that reduction in NEP and IDE activity is not the primary cause of beta-amyloid accumulation in AD, but rather a late-stage phenomenon secondary to neurodegeneration...
  7. doi Abeta-degrading enzymes in Alzheimer's disease
    James Scott Miners
    Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK
    Brain Pathol 18:240-52. 2008
    ....